New and notable appointments at Heneghan Strategic Communications, Actavo, Sodexo, Neuromod Devices Ltd, and Baker Tilly Mooney Moore. 

For the past four years, Stevenson has worked in Sodexo’s Global Strategic Accounts team, where she has led the prestigious account of one of the worlds’ largest healthcare companies as the Global Account Director. Her experience includes 30 years in facilities and project management, spanning a range of sectors. Her vast knowledge of integrated facilities management has nurtured her talent as a skilled negotiator, strong leader and strategic thinker. 

Escolme joins Sodexo from restaurant chain Itsu, where she was Marketing Director. She also has over 20 years of experience in marketing for leading global FMCG, retail and leisure brands across multiple international markets. In her new role, Escolme will lead the UK and Ireland Marketing function and will be responsible for the client and consumer marketing strategy for Corporate Services in the UK and Ireland.

Cheema has worked in Sodexo’s Service Operations team, where he led the Digital and Promotions team for the past four years. Cheema brings innovation and thought leadership and has been instrumental in Sodexo’s activity to enable the business to return safely and has played an essential role as co-chair of the Origins group, which encourages inclusivity and cohesion by celebrating the diversity of culture. In his new role, Cheema will lead the development, deployment, performance management and awareness building of Workplace Services.

Julie Ennis, CEO Corporate Services Sodexo UK & Ireland, said: “With the lifting of the work from home guidance in England, our clients need our expertise more than ever to help them to transform their workplaces as we begin a new way of working and as society starts to open up fully.

“I’m delighted to have Paula, Libby and Harpreet on board as we continue to develop our Workplace Services and strengthen our Vital Spaces value proposition, which will help empower clients to transform their workplaces in both the short and long-term.”

Stephanie Glowacki, Dr. Tish Ramirez, Holly Dean, Chief Financial Officer, Chief Commercial Officer, Director & Commercial Sales, respectively,
Neuromod Devices Ltd

Neuromod Devices Ltd, the Irish medical device company specialising in the treatment of tinnitus, has announced the establishment of Neuromod USA Inc., a subsidiary headquartered in Oak Brook, Illinois.

Three executives with significant experience in the hearing health industry have been appointed to Neuromod USA’s leadership team as the organization prepares to enter the US market with its medical device for tinnitus treatment, pending approval from the Food and Drug Administration.

Stephanie Glowacki joins the organization as Chief Financial Officer. In this role she is responsible for the creation and management of Neuromod USA’s operating infrastructure, including finance, human resources and operations. Stephanie joins from WS Audiology where she held positions in finance, sales operations and as chief of staff to the wholesale Chief Executive Officer. Prior to that, she held positions of increasing responsibility in sales operations and corporate finance at Sivantos, Phonak, Tellabs and Andersen Consulting/Accenture. Stephanie holds a BA degree in economics and business from Hanover College.

Dr. Tish Ramirez (AuD) has joined the US organization as Chief Commercial Officer. In this position she is responsible for customers, interactions with consumers, as well as offering, launching, and introducing products to meet Neuromod USA’s strategic commercial objectives. Before Neuromod, Tish was vice president of clinical education and product management for WSAudiology. Prior to this, she held roles in clinical education, sales management and as a clinical audiologist at Sivantos/Siemens, Phonak and CIGNA Healthcare. Tish holds a doctorate degree in Audiology from A.T. Still University, an MS from Arizona State University and a BS degree from the University of Arizona.

Holly Dean joins Neuromod USA as Director, Commercial Sales. In this role she oversees Neuromod USA’s sales activities to private practices. Holly comes to the organization from WSAudiology where she held the position of Director of National Accounts. In that role, she led a team that provided substantial growth within the buying groups, third party, insurance and medical channels. Before WSAudiology, Holly held positions of increasing responsibility in sales leadership and territory management at Sivantos, Phonak and Sunovian Pharmaceuticals. Holly holds a BS degree from Louisiana State University.

Collectively, Neuromod USA’s leadership team will lead the development of the organization’s strategy to work with the private and public hearing healthcare ecosystem to bring Neuromod’s interventions for tinnitus to patients in the US.

Tinnitus is believed to affect between 10 and 15% of the global population and is commonly described as ‘ringing in the ears’. In the United States, tinnitus remains a significant healthcare need as it’s estimated that almost 50 million people suffer from this neurological condition. Of these, roughly 20 million people struggle with burdensome chronic tinnitus.

According to the United States Department of Veteran Affairs, more than two million US Veterans receive disability payments for service-connected tinnitus. This unmet clinic need makes tinnitus the department’s largest and fastest growing cause of service-connected disability.

Dr. Ross O’Neill, Founder and Chief Executive Officer at Neuromod Devices Ltd. commented on the recent developments in the US, saying “In order to give ourselves the fastest start to meet the needs of the estimated 50 million people in the USA with tinnitus, we are developing our US infrastructure. I am personally energized by the quality of talent joining the company and look forward to working with them on addressing the needs of the world’s largest tinnitus market.”

Neuromod specializes in non-invasive neuromodulation technologies and has developed Lenire, the first non-invasive bimodal neuromodulation device for the treatment of tinnitus which has shown in large-scale clinical trials to reduce the symptoms of tinnitus. Lenire has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe. In October 2020, Neuromod announced it raised €10.5 million in an oversubscribed Series B financing round to fund ongoing expansion of the availability of Lenire in Europe and the organization’s FDA submission process in the US for the approval for Lenire.

Eimear Brown, Head of Audit, 
Baker Tilly Mooney Moore.

Baker Tilly Mooney Moore, A Northern Ireland accountancy and advisory firm, has appointed Eimear Brown as its new Head of Audit.

The senior appointment comes in a period of sustained growth for the established firm, which specialises in Audit & Assurance, Taxation, Restructuring & Insolvency and Consulting.

Eimear joins the well-known accountancy brand with over 16 years of experience in roles in Dublin and Belfast, both in ‘big 4’ and ‘mid-tier’ practices.

Commenting on the new appointment, Joanne Small, Audit & Assurance Partner at Baker Tilly Mooney Moore said: “This is a significant hire for us at Baker Tilly Mooney Moore and is a real statement of intent for the business, adding another highly respected and trusted adviser to our ambitious team.”

“Eimear brings with her a wealth of experience and insight gained in previous senior positions in Dublin and Belfast and will play a critical role as we enhance our services for our established and new clients.”

 “As the new Head of Audit, Eimear will also be responsible for staff training and development, ensuring that our exacting standards are maintained across our team. Her leadership skills and her sense of purpose will have significant impact as we emerge post pandemic.”

Eimear Brown, new Director and Head of Audit at Baker Tilly Mooney Moore added: “I am thrilled to be joining the Baker Tilly Mooney Moore team during a period of expansion at the firm. I am hopeful that as our clients get back to business, back trading, and back to full operations, that the future will be one of positive economic growth. It’s the right time to join such a highly regarded and dedicated firm.”

 She added: “The evolving regulatory environment means that there are always new challenges that provide opportunities for firms such as Baker Tilly Mooney Moore to stand out and I’m looking forward to embracing those.”

 “Dealing with the outworking of the pandemic, the new trading environment shaped by Brexit, and the increased emphasis on Environmental, Social and Governance (ESG) reporting, has placed extra pressures on businesses and organisations and I am confident that our team can rise to those challenges, making sure our clients are in the best position.”